Note 5 - Notes Receivable (Details Textual) - CytoBioscience [Member] - Promissory Notes Receivable [Member]	Sep. 30, 2019 USD ($)
Financing Receivable, after Allowance for Credit Loss, Total	$ 1,112,524
Notes Receivable, Interest Rate, Stated Percentage	8.00%
Note Receivable, Collateral Value	$ 1,290,000
Note Receivable Collateral Fair Value	$ 250,000

Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522

Name:	us-gaap_NotesReceivableNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant